S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Is Gold Really Boring? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Critical asset just had biggest fall on record (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Is Gold Really Boring? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Critical asset just had biggest fall on record (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Is Gold Really Boring? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Critical asset just had biggest fall on record (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Is Gold Really Boring? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Critical asset just had biggest fall on record (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
NYSE:GEN

Genesis Healthcare (GEN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$21.36
$21.67
50-Day Range
$0.18
$0.60
52-Week Range
$0.40
$1.37
Volume
2.46 million shs
Average Volume
4.10 million shs
Market Capitalization
$13.69 billion
P/E Ratio
23.80
Dividend Yield
2.33%
Price Target
$25.60

Genesis Healthcare MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
19.5% Upside
$25.60 Price Target
Short Interest
N/A
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
0.00mentions of Genesis Healthcare in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
5.52%
From $1.63 to $1.72 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.19 out of 5 stars

Business Services Sector

181st out of 298 stocks

Prepackaged Software Industry

127th out of 195 stocks


GEN stock logo

About Genesis Healthcare Stock (NYSE:GEN)

Genesis Healthcare, Inc., together with its subsidiaries, owns and operates skilled nursing facilities and assisted/senior living facilities in the United States. The company operates through three segments: Inpatient Services; Rehabilitation Therapy Services; and Other Services. It also provides a range of rehabilitation therapy services, including speech-language pathology, physical therapy, occupational therapy, and respiratory therapy. In addition, the company offers other specialty medical services, such as physician, staffing, and other healthcare related services. As of December 31, 2020, it provided inpatient services through a network of approximately 341 skilled nursing facilities and assisted/senior living communities in 24 states; and supplied rehabilitation and respiratory therapy to approximately 1,400 healthcare locations in 42 states, the District of Columbia and China. The company was formerly known as FC-GEN Operations Investment, LLC and changed its name to Genesis HealthCare, Inc. in February 2015. Genesis HealthCare, Inc. was founded in 2003 and is headquartered in Kennett Square, Pennsylvania.


GEN Stock News Headlines

Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?
A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.
Walk-In Wednesdays hiring events back at Genesis
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?
A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.
See More Headlines
Receive GEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genesis Healthcare and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 12/13 Dividend
11/17/2023
Dividend Payable
12/13/2023
Last Earnings
2/01/2024
Ex-Dividend for 3/13 Dividend
2/15/2024
Today
2/27/2024
Dividend Payable
3/13/2024
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Prepackaged software
Sub-Industry
N/A
Employees
2,700
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$25.60
High Stock Price Target
$28.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+19.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$836 million
Pretax Margin
23.69%

Debt

Sales & Book Value

Annual Sales
$2.80 billion
Cash Flow
$2.54 per share
Book Value
($0.16) per share

Miscellaneous

Free Float
618,038,000
Market Cap
$13.69 billion
Optionable
Optionable
Beta
0.84
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Robert H. Fish (Age 70)
    CEO & Director
    Comp: $411.5k
  • Mr. Thomas DiVittorio (Age 53)
    Exec. VP & CFO
    Comp: $565k
  • Mr. Paul David Bach (Age 62)
    COO & Exec. VP
    Comp: $630k
  • Mr. Stephen Scott Young (Age 49)
    Chief Accounting Officer & Treasurer
  • Mr. Richard L. Castor (Age 66)
    Chief Information Officer & Sr. VP
  • Mr. James W. Tabak (Age 62)
    Sr. VP of Admin. & Gov. Affairs
  • Ms. Lori Mayer
    VP of Investor Relations, Brand Management & Marketing Communications
  • Mr. Michael Scott Sherman (Age 52)
    Sr. VP, Gen. Counsel, Sec. & Assistant Treasurer
  • Mr. Larry Baider
    Sr. VP of People Strategy & Operations
  • Dr. JoAnne Susan Reifsnyder R.N. (Age 62)
    Ph.D., Ph.D., ACHPN, MSN, MBA, RN, FAAN, Exec. VP of Clinical Operations & Chief Nursing Officer














GEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Genesis Healthcare stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genesis Healthcare in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GEN shares.
View GEN analyst ratings
or view top-rated stocks.

What is Genesis Healthcare's stock price target for 2024?

5 brokerages have issued 1 year price objectives for Genesis Healthcare's stock. Their GEN share price targets range from $23.00 to $28.00. On average, they anticipate the company's stock price to reach $25.60 in the next twelve months. This suggests a possible upside of 19.5% from the stock's current price.
View analysts price targets for GEN
or view top-rated stocks among Wall Street analysts.

How were Genesis Healthcare's earnings last quarter?

Genesis Healthcare, Inc. (NYSE:GEN) issued its earnings results on Thursday, February, 1st. The company reported $0.45 earnings per share for the quarter, meeting the consensus estimate of $0.45. The business had revenue of $953 million for the quarter, compared to analysts' expectations of $955.80 million. Genesis Healthcare had a net margin of 17.83% and a trailing twelve-month return on equity of 155.48%.

How often does Genesis Healthcare pay dividends? What is the dividend yield for Genesis Healthcare?

Genesis Healthcare declared a quarterly dividend on Thursday, February 1st. Stockholders of record on Monday, February 19th will be paid a dividend of $0.125 per share on Wednesday, March 13th. This represents a $0.50 dividend on an annualized basis and a yield of 2.33%. The ex-dividend date of this dividend is Thursday, February 15th.
Read our dividend analysis for GEN
.

Is Genesis Healthcare a good dividend stock?

Genesis Healthcare (NYSE:GEN) pays an annual dividend of $0.50 per share and currently has a dividend yield of 3.05%. The dividend payout ratio is 55.56%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GEN will have a dividend payout ratio of 29.07% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GEN.

What guidance has Genesis Healthcare issued on next quarter's earnings?

Genesis Healthcare updated its fourth quarter 2024 earnings guidance on Thursday, February, 1st. The company provided earnings per share guidance of 0.520-0.540 for the period, compared to the consensus EPS estimate of 0.530. The company issued revenue guidance of $960.0 million-$970.0 million, compared to the consensus revenue estimate of $974.4 million.

What other stocks do shareholders of Genesis Healthcare own?
Who are Genesis Healthcare's major shareholders?

Genesis Healthcare's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.57%), Boston Partners (2.76%), Beutel Goodman & Co Ltd. (2.05%), Legal & General Group Plc (1.80%), Franklin Resources Inc. (1.76%) and First Trust Advisors LP (1.54%). Insiders that own company stock include Natalie Marie Derse and Ondrej Vlcek.
View institutional ownership trends
.

This page (NYSE:GEN) was last updated on 2/28/2024 by MarketBeat.com Staff